Immunitybio Inc (IBRX) — Cash Flow-to-Debt Ratio
Immunitybio Inc (IBRX) has a Cash Flow-to-Debt Ratio of -0.12x as of September 2025, meaning its operating cash flow of $-68.91 Million could theoretically repay 0% of its total liabilities ($569.82 Million) in one year. See Immunitybio Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Immunitybio Inc Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Immunitybio Inc across 12 annual periods. Also explore Immunitybio Inc (IBRX) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Immunitybio Inc (2013–2024)
Year-by-year debt coverage analysis for Immunitybio Inc. For market capitalisation and broader financial context, see Immunitybio Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.45x | $-391.24 Million | $871.06 Million | ▼ -33.5% |
| 2023 | -0.34x | $-366.76 Million | $1.09 Billion | ▲ +19.1% |
| 2022 | -0.42x | $-337.51 Million | $812.18 Million | ▼ -7.9% |
| 2021 | -0.38x | $-274.42 Million | $712.82 Million | ▲ +23.8% |
| 2020 | -0.51x | $-171.72 Million | $339.87 Million | ▲ +92.5% |
| 2019 | -6.78x | $-152.11 Million | $22.44 Million | ▼ -284.3% |
| 2018 | -1.76x | $-63.38 Million | $35.94 Million | ▼ -14.2% |
| 2017 | -1.54x | $-48.78 Million | $31.60 Million | ▲ +3.7% |
| 2016 | -1.60x | $-38.59 Million | $24.08 Million | ▲ +31.3% |
| 2015 | -2.33x | $-25.30 Million | $10.85 Million | ▼ -4.7% |
| 2014 | -2.23x | $-5.35 Million | $2.40 Million | ▼ -1565.6% |
| 2013 | -0.13x | $-668.00K | $5.00 Million | — |